Isolation of Methicillin Resistant Staphylococcus aureus (module 2011) in Taif Area, Saudi Arabia

Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium responsible for several difficult-to-treat infections in humans. It may be named multidrug-resistant S. aureus or Oxacillin-resistant S. aureus (ORSA). MRSA is a strain of S. aureus that developed resistance to β-Lactam antibiotics, including Penicillins, which include (Methicillin, Dicloxacillin, Nafcillin, Oxacillin, etc.) and Cephalosporine. The aim of this studt was to investigate the new MRSA strain from patient in Taif area who complained from chronic prostatitis and clinically uncured with treatment by Amoxicillin antibiotics for two months; after that the patient was treated by Quinolones antibiotics for three weeks and he was clinically cured. The causative strain isolated was reinvestigated with antibiotics groups to confirm that it is a new module of MRSA that has a different antibiotics sensitivity characterestics in Taif area. The results revealed that the MRSA tested was resistant to antibiotics groups β-Lactam (Penicillin, Oxacillin, Ampicillin and Augmentin) and Glycopeptides (Vancomycin) and of intermediate sensitivity to Macrolides (Erythromycin, Clindamycin and Azithromycin), Aminoglycosides (Gentamycin) and sensitive to Nitrofurantoin from Macrolides, Amikacin from Aminoglycosides and (Ciprofloxacin, Ofloxacin and Norfloxacin) from Quinolones. The study revealed the resistance of new isolated MRSA strain and its sensitivity to little groups of antibiotics that lead to serious health problems if the sensitive antibiotics turned to be resistant or unavailable treated antibiotics in the area. MRSA, widely dangerous for human health as well resistant to antibiotics, is used increasing by time due to fast changes in the genome of S.aureus and the misuse of antibiotics by patients. Further studies are required to improve the interaction between human infections by MRSA, prevention, slowering resistant of MRSA and new strong sensitive antibiotics production